Please ensure Javascript is enabled for purposes of website accessibility

Is Moderna Stock Overvalued?

By Keith Speights and Brian Orelli, PhD - Feb 10, 2021 at 6:14AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One Wall Street analyst thinks so.

Moderna (MRNA -4.97%) stock skyrocketed last year. Its momentum has carried over into 2021 as well. After its tremendous gains, the biotech's market cap is now well over $60 billion. In this Motley Fool Live video recorded on Feb. 3, 2021, Fool.com contributors Keith Speights and Brian Orelli talk about whether Moderna stock is now overvalued after its remarkable run.

Keith Speights: Bank of America downgraded Moderna this week to underperform from neutral. Agree or disagree with this move?

Brian Orelli: I mean, I've been saying Moderna was overpriced for months now. I was not wrong, so I don't know. I mean, I think it's a really high valuation with its [...] market cap. I think, if you assume $15 billion in sales, that's a price-to-sales ratio of 4. That's pricing it like they're not going to continue to earn $15 billion in sales or that they're going to have $15 billion in sales continuing but it's not really going to grow much beyond that for the foreseeable future. I think that's a reasonable valuation if you assume that they're going to be able to continue selling coronavirus vaccines and or get the rest of their pipeline into sales fairly quickly.

Speights: It's important to remember that Wall Street analysts are looking at the short term, and over the short term, Moderna probably doesn't have many catalysts that are going to bump that stock much higher. Over the long term, they could be a platform company with their messenger RNA technology and so I think investors should keep that in mind. Differentiate between short-term thinking and long-term thinking with any stock but especially a stock like Moderna.

Orelli: Yeah. I think if you're going to buy it, you have to be planning on buying it for a while, because it certainly could go down from here before it goes higher.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$136.25 (-4.97%) $-7.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.